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Abstract 
Background: Several promising biomarkers have been found for RCC, but none of them has been used in clinical 
practice for predicting tumour progression. The most widely used features for predicting tumour aggressiveness still 
remain the cancer stage, size and grade. Therefore, the aim of our study is to investigate the urinary peptidome to 
search and identify peptides whose concentrations in urine are linked to tumour growth measure and clinical data.
Methods: A proteomic approach applied to ccRCC urinary peptidome (n = 117) based on prefractionation with 
activated magnetic beads followed by MALDI-TOF profiling was used. A systematic correlation study was performed 
on urinary peptide profiles obtained from MS analysis. Peptide identity was obtained by LC–ESI–MS/MS.
Results: Fifteen, twenty-six and five peptides showed a statistically significant alteration of their urinary concen-
tration according to tumour size, pT and grade, respectively. Furthermore, 15 and 9 signals were observed to have 
urinary levels statistically modified in patients at different pT or grade values, even at very early stages. Among them, 
C1RL, A1AGx, ZAG2G, PGBM, MMP23, GP162, ADA19, G3P, RSPH3, DREB, NOTC2 SAFB2 and CC168 were identified.
Conclusions: We identified several peptides whose urinary abundance varied according to tumour size, stage and 
grade. Among them, several play a possible role in tumorigenesis, progression and aggressiveness. These results could 
be a useful starting point for future studies aimed at verifying their possible use in the managements of RCC patients.
Keywords: Mass spectrometry, Proteomics, Urine, Renal cell carcinoma, Tumour size, Tumour progression, Stage, 
Grade, Cancer, Peptidomics
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Background
Renal cell cancer (RCC) accounts for about 4  % of all 
adult cancers and is the most dangerous of all urological 
malignancies with a median survival time of about 
13  months, with less than 10  % of patients surviving 
more than 5  years. There are about 210,000 new cases 
and 100,000 deaths diagnosed worldwide every year, and 
the number of patients is increasing rapidly [1]. About 
30  % of patients already have metastasis at the time of 
diagnosis and 30–40 % of patients with localized kidney 
cancer will have a recurrence [2]. Although partial or 
total surgical resection are the gold standard treatments 
for patients with localized RCC, approximately 
20–40 % of them will have progression during one-year 
follow-up  period. Neither chemotherapy nor radiation 
therapy is effective for the patients with metastases [1].
Over the last decade, most of kidney tumours are 
revealed incidentally during unrelated clinical investigation, 
owing to the widespread use of abdominal imaging, 
including ultrasonography and computed tomography. 
Moreover, laboratory examinations accompanied by urine 
analysis in search for haematuria are prompted for every 
suspicion of RCC [3]; however, there are still no other 
cancer type- or stage specific biomarkers appropriate for 
clinical usage in urine analysis [4]. On the other hand, the 
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increase of RCC incidence is also associated with the rise 
in incidental detection of localized small renal masses. 
About 20 % of small masses are benign and they are likely 
to have pathological characteristics of low Fuhrman grade 
and clear cell type. In addition, small renal masses are 
increasingly detected in elderly patients who probably 
have comorbidities and are a high-risk group for active 
treatment like surgery [5]. Consequently, indications 
for watchful-waiting in small renal kidney cancers are 
consistently expanding [6]. As the management possibilities 
are enhancing, the current role of renal mass biopsy is also 
increasing. Thus, despite the associated risks (bleeding, 
tumor seeding, etc.), renal mass biopsy is recommended 
for active surveillance in most cases except in watchful-
waiting candidates, in patients with imaging or clinical 
characteristics indicative of pathology as syndromes 
and in cases whereby conservative management is not 
contemplated [7].
Rapid progress has been made to understand 
tumorigenesis, but the key events leading to the 
dysfunction of the control of cellular proliferation still 
remain unclear. Since alterations of these regulatory 
processes can be caused not only by altered gene 
expression but also by proteins, proteomics investigations 
are of special importance to detect patterns of disease-
associated protein alterations. Recently, we and 
other researchers used these approaches to identify 
differentially expressed proteins by comparing non-
neoplastic and neoplastic kidney tissue as possible 
biomarkers [8–10]. Moreover, biomarker discovery for 
RCC is not only feasible in the tissue proteome but also 
in urinary peptidome. In fact, peptidomics analysis has 
detected the presence of clusters of urinary peptides able 
not only to differentiate RCC patients from controls [11] 
but even benign from malignant kidney solid masses [12].
Following surgery, TNM (Tumour-Node-Metastasis) 
staging and Fuhrman grade as well as performance 
status and serum markers (haemoglobin, calcium, lactate 
dehydrogenase, platelets, neutrophils and C-reactive 
protein) are the most used factors applied so far for 
predicting tumour progression and recurrence [13]. 
Many authors have therefore investigated the role of 
prognostic biomarkers attempting to improve patient’s 
risk stratification, and better predict disease recurrence 
and associated mortality [13, 14]. Quite recently, a 
predictive model based on the following independent 
prognostic factors has been published by Tosco et  al. 
[15]: primary tumour T stage ≥3, primary tumour 
Fuhrman grade ≥3, nonpulmonary metastases, disease-
free interval ≤12 mo and multiorgan metastases. 
Considering that cancer progression is reflected by 
tumour stages, Junker et  al. have examined neoplastic 
tissues from kidneys belonging to different stages 
and grades as well as the non-neoplastic specimen 
counterparty [10]. In particular, they have studied the 
proteome of kidney tissue of 27 patients (pT1, pT2, pT3) 
and 9 adjacent normal tissue by 2D-DIGE, identifying 
several proteins correlating with pT. Lebdaj et  al. 
found a significant association between expression of 
transforming growth factor beta-induced (TGFBI) in 
tissue with tumour category pT3-pT4, Fuhrman grades 
III and IV and tumour mass size >4 cm [16]. Moreover, 
Morrisey et  al. have observed a correlation between 
the neoplasm size and the pre-nephrectomy urinary 
levels of AQP1 and PLIN2. A correlation was found 
also for both markers with tumour stage but not with 
grade [17]. The identification of biomarkers predicting 
treatment response could avoid unnecessary costs, 
prevent side effects, and help in choosing optimal patient 
management. Recently, progress in the chemotherapeutic 
treatment of renal cell carcinomas has been achieved 
with the development of targeted molecular therapies 
[16]. Currently, several promising molecular biomarkers 
have been found, but none of them have been introduced 
in clinical practice. Consequently, the most powerful tool 
for predicting tumour aggressiveness still remains stage, 
size and grade [16]. However, as it stands, no systematic 
investigation has been carried out to highlight if part of 
the urinary peptidome not only suggests the presence of 
a tumour mass in kidney [11, 12] but may also reflect its 
progression. Therefore, in this study we investigated the 
urinary peptidome to search  for and identify peptides 
with a urinary expression alteration according to pT, 
tumour dimension and grade to be employed as a 
possible starting point for future more specific studies 
aimed at ccRCC management.
Methods
Chemicals and standards
Profiling Kit 1000 C8-MB, α-cyano-4-hydroxycinnamic 
acid (CHCA), Protein Calibration Standard I (Prot-
Mix I) and Peptide Calibration Standard II (PepMix II) 
were provided by Bruker Daltonics GmbH (Bremen, 
Germany).
Urine collection and handling procedure
Urine samples were collected from patients the day 
before surgery at “Ospedale Maggiore Policlinico” 
Foundation (Milan, Italy), San Gerardo Hospital 
(Monza, Italy) and those from healthy volunteers at 
Desio Hospital (Desio, Italy). All subjects had signed an 
informed consent prior to sample donation and analyses 
were carried out in agreement with the Declaration 
of Helsinki. Study protocols and procedures were 
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approved by the local ethic committee (U.O. Comitato 
di Etica e Sperimentazione Farmaci Direzione Scientifica 
Fondazione IRCCS Ca’Granda Ospedale Maggiore 
Policlinico, Milano and Comitato Etico Azienda 
Ospedaliera San Gerardo, Monza, Italy). Second morning 
midstream urine was collected in sterile urine tubes 
(Anicrin s.r.l., Italy) [18].
Prefractionation of urine samples was performed as 
already described [12]. Briefly, 40  µL of  the urine sam-
ple was incubated for 1 min in a magnetic separator with 
80 µL of binding buffer and 5 µL of RPC8 magnetic beads. 
The beads were then washed twice with 45 µL and once 
with 30 µL of washing solution. Finally, the peptides were 
released with 10 µL of elution solution (50 % Acetonitrile 
in water). A small amount of the eluates was used for the 
automated spotting onto an AnchorChip™ target (Bruker 
Daltonics, Germany).
In addition, two pools were obtained by mixing 40 µL 
of urine of each subject and used for peptide identifica-
tion. The two pools were manually purified with mag-
netic beads following the same steps and proportion 
described for the automatic procedure.
MALDI‑TOF peptide profiling
The analysis of purified urine samples was performed in 
linear mode (MALDI-LM) and reflector mode (MALDI-
RM) using an UltrafleXtreme™ MALDI-TOF/TOF 
instrument (Bruker Daltonics, Germany) [19].
Multiple spectra comparison was performed with 
ClinProTools™ Software v. 2.2 (Bruker Daltonics, Ger-
many) after normalization. Statistical elaboration was 
conducted on the mean spectrum generated from each 
subject dataset. A S/N threshold of 3 and zero level inte-
gration type were used as parameters in order to obtain a 
list of peaks with their area, calculated on the total aver-
age spectrum.
Expression profile analysis and statistical analysis
Statistical analysis was conducted as already described 
[12]. Initially normality and homogeneity of variance 
(Shapiro–Wilk’s, Barlett and Leven’s test for normality 
and homogeneity testing) were evaluated, followed by 
suitable parametric or non-parametric tests for groups 
comparisons (Equal Variance t test for Normal Data 
with Equal Variances, Unequal Variance (Welch) t-test 
for Normal Data with Unequal Variances, Mann–
Whitney U-test (Wilcoxon) for Non-normal Data with 
Equal Variances and Kolmogorov–Smirnov test for 
Non-normal Data with Unequal Variances). Peptide 
urinary expression variation according to clinical data 
was computed using Spearman rank-order correlation 
(Spearman’s rho). All tests were applied using 0.05 as the 
significance level.
Peptide sequencing by nLC–ESI–MS/MS
Identity of the endogenous peptides present in RPC8 
enriched fractions were assessed by nLC–ESI–MS/
MS analysis of the ccRCC patients urine pool (n =  80) 
prepared as previously described [19]. Briefly, before 
injection MB fractionated samples underwent a 
purification step from salts and beads performed using 
Ziptip™ μ-C18 Pipette Tips (Millipore Corp, Bedford, 
MA, USA) as already reported [19]. Desalted fractions 
were chromatographically separated into a Dionex 
UltiMate 3000 rapid separation (RS) LC nano system 
(Thermo Scientific, Germany) and analysed with an 
online-coupled Impact HD™ mass spectrometer (Bruker 
Daltonics, Germany).
Peptides were loaded onto a µ-precolumn (Dionex, 
Acclaim PepMap 100 C18, cartridge, 300 µm i.d. × 5 mm, 
5  µm), followed by a multistep 360  min gradient at 
a flow rate of 300  nl/min on the analytical 50  cm nano 
column (Dionex, 0.075  mm ID, Acclaim PepMap100, 
C18, 2 µm). A ramp from 4 to 35 % in 245 min of mobile 
phase B (0.1  % FA/80  % CHCN) was used. The column 
was connected to a nanoBooster CaptiveSpray™ (Bruker 
Daltonics). The mass spectrometer was operated in 
the data-dependent-acquisition mode to automatically 
switch between full scan MS and MS/MS acquisition in 
CID mode (N2 was used as collision gas). The number 
of precursor ions was automatically adjusted to fit into a 
fixed cycle time of 5  s, and IDAS (Intensity Dependent 
Acquisition Speed) and RT2 (RealTime Re-Think) func-
tionalities were applied. The tune parameters were set as 
already described [12] in order to better assist the frag-
mentation of larger endogenous peptides.
XML peaklists were processed using an in-house 
Mascot search engine (v2.4.1). Database searching was 
restricted to human Swiss-Prot (accessed Apr 2015, 
548,208 sequences; 195,282,524 residues). Mass toler-
ances were set at 20  ppm for MS and 0.05  Da for MS/
MS. No enzyme and any fixed modification was set in the 
search parameters. Acetyl (N-term), Acetyl (K), Deami-
dation (NQ), Oxidation (HW), Oxidation (M) were set as 
variable modifications in the Mascot search parameters. 
Mascot score thresholds and decoy database were used as 
peptide level filters of peptide significance (FDR <5 %).
Results
Clinical data and study design
Urine collected from 117 clear cell RCC patients (ccRCC) 
(72 men, 45 women) were used in the present study. 
Fisher test did not reveal any gender dependence in the 
studied cohort. The mean age for patients was 64.05 
with a range of 33–87  years. Patients were classified 
according to the 2009 TNM system classification and 
their clinical characteristics are described in Table 1 [12]. 
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Histological analysis was performed on patients based 
upon the Fuhrman grading system, sarcomatoid and 
cystic differentiation, tumour necrosis, microvascularity 
and urinary infiltration. Dimension of the tumour mass 
was in the range from 1.5 to 18 cm. RCC patients were 
divided in four groups according to pT (group 1 = pT1a; 
2 = pT1b; 3 = pT2a and 4 = pT ≥ 2b) or Grade values 
(1, 2, 3 and 4). Urine samples collected from 137 healthy 
subjects (81 men, 56 women) were used for statistical 
analysis [12].
Peptide urinary expression altered according to clinical 
data
To investigate the possible association between urinary 
levels of peptides and tumour size, pT and grade, statisti-
cal analysis was applied to the peptidomic profiles of the 
ccRCC patients. Peptides with a urinary expression cor-
relating with age were not considered [12].
Urinary peptides varied depending on tumour size
Fifteen peptides showed a statistically significant vari-
ation according to tumour size (Additional file  1: 
Table  S1A). Almost all of these peptides  also have a 
statistically different expression from control subjects 
(Additional file  1: Table  S1A, second column). Interest-
ingly, the alteration was negative for three of them (range 
from −0.307 to −0.312) and positive for the other twelve 
(range from 0.31 to 0.514).
Peptide urinary expression altered according to pT
Twenty-six peptides displayed a statistically significant 
variation between their urinary concentration and pT 
(Additional file  2: Table  S2A). Fifteen of these peptides 
were differentially expressed in RCC compared with 
controls (Additional file  2: Table  S2A, second column). 
Notably, only five of them showed a negative alteration 
(range from −0.202 to −0.326) while for the other 
twenty-one the variation was positive (range from 0.203 
to 0.27).
Urinary peptides altered according to Grade
Only five peptides showed a statistically significant alter-
ation between their urinary concentration and grade 
(Additional file  3: Table  S3A). Four peptides were sig-
nificantly differentially expressed between patients and 
controls (Additional file  3: Table  S3A, second column). 
Only one of them showed a positive variation while for 
the other four it was negative with a value of about −0.2.
Urinary peptides differentially expressed according 
to histological data
To investigate the possible alterations of the urinary 
levels of peptides according to pT and Grade, statisti-
cal analysis was applied to the peptidomic profiles of the 
RCC patients divided into four groups.
Fifteen peptides were observed to have urinary lev-
els statistically different in patients at different pT val-
ues (Additional file 2: Table S2B, Figs. 1, 2), and nine of 
them were significantly also varied in patients compared 
with control subjects (Additional file 2: Table S2B, second 
column). Furthermore, considering only the compari-
son between patients with tumour stage pT1a and pT1b, 
fourteen peptides showed a statistically significant altera-
tion (Additional file 4: Table S4). 
On the contrary, nine peptides (Additional file  3: 
Table  S3B, Figs.  1, 2) showed a statistically significant 
difference between patients having a tumour at different 
grades, with seven of them also varied in patients ver-
sus healthy subjects (Additional file 3: Table S3B, second 
column).
Peptide identification
Identity of the urinary peptides in the C8-magnetic beads 
pre-purified fractions was obtained by nanoLC-ESI–MS/
MS. Several peptides could be identified and among 
them, fifteen signals having a variation linked to clinical 
data were recognized (Additional file 5: Table S5).
Six ions present in MALDI-LM profiles and not 
in MALDI-RM spectra were matched with peptide 
sequences identified in ESI–MS/MS (average Mass 
Measurement errors for LM: 222 ± 411.1 ppm): the ion 
at m/z 3571.1 was recognized as the fragment 362SQP 
Table 1 Patients clinical characteristics according to  the 
2009 TNM (tumour-node-metastasis) system classification
No. of patients
ALL 117
Mean ± SD age at diagnosis 64.05 ± 11.16
Median age at diagnosis (range) 33–87
Tumor mass in cm (range) 1.5–18
Gender
 Males 72
 Females 45
Staging
 pT1a 45
 pT1b 39
 pT2a 23
 pT2b 1
 pT3a 9
 pT3b 0
Grade
 1 6
 2 79
 3 20
 4 3
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Fig. 1 Box-plot of identified peptides (below 2500 m/z) that resulted statistically varied according to class (CTRLs vs ccRCC) pT or grade. The pos-
sible significant correlation with tumor size, TNM stage and Fuhrman grade is reported
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Fig. 2 Box-plot of identified peptides (above 2500 m/z) that resulted statistically varied according to class (CTRLs vs ccRCC) pT or grade. The pos-
sible significant correlation with tumor size, TNM stage and Fuhrman grade is reported
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PPLPPPPPPAQETQEPSPILDSEETRAAAPQ395 of the 
DREB protein; the ion at 3723.8 as the 51 STHGKFHGTV 
KAENGKLVINGNPITIFQERDPSK84 fragment origi-
nated from G3P_HUMAN; the ion at m/z 4355.1 as the 
acetylated form of the 386EEKDIKPIIKDEKGRVGSGS-
GRNLWVSGLSSTTRATDLK424 peptide belonging to 
the SAFB2 protein; the ion at m/z 4626.9 as the 868HEVK-
TIDMRFRIHCQEARISPMSHILNAKELVLNINKLE906 
fragment from CC168 protein. The remaining nine of the 
fifteen signals were also detected in MALDI-RM profiles, 
strengthening the accuracy of identity assignment (aver-
age Mass Measurement errors for RM: 36.7 ± 81.3 ppm).
In particular, the ion at m/z 1755.8 was identified as a 
peptide deriving from A1AGx, which is common to both 
A1AG1 and A1AG2 protein isoforms. The ion at m/z 
1934.2 could be generated from two different peptides, 
whose masses could not be unequivocally assigned 
observing the isotope cluster obtained in MALDI-RM: 
the fragment 1152ERLEEAGGATSAQIEMNK1169 deriving 
from the MYH1_HUMAN/MYH4_HUMAN or/and 
the fragment 40LGAPAVPAWSAAQGDVAALGL60 
originating from the MMP23 protein. Similarly, the ion 
at m/z 1825.6 could be ascribed to amino acid sequence 
59FRYNSKDRKSQPMGL73 of ZA2G_HUMAN and/or 
to 4283VSEDPINDGEWHRVTA4298 peptide of PGBM_
HUMAN. For two of the thirteen signals (m/z 2192.1 
and m/z 3151.1), the resolving power of MALDI-RM and 
the low mass difference between different amino acid 
sequences identified by ESI MS/MS have not allowed 
the specific contributes to MALDI-LM peak  to be 
unambiguously distinguished.
Three signals were attributed to the same specific 
amino acid sequences reported in our previous papers 
[12, 18]. The ion at m/z 1912.1 was already identified as 
an UROM fragment [18], the ion at m/z 2192.1 as two 
possible peptides belonging to GP162_HUMAN and/
or KPB1_HUMAN [12], while the ion at m/z 2660.8 was 
unambiguously identified as a fragment from FIBA, also 
by MALDI MS/MS analysis [12].
Discussion
Renal cell carcinoma, the most common type of human 
kidney cancer, is increasing in incidence and it is the most 
lethal genitourinary malignancy. Several studies aiming at 
biomarker discovery in RCC have been reported in recent 
years. Most of them deal with the search of markers for 
early diagnosis, for prognosis and for the prediction of 
patients’ response to therapy. Several proteins correlating 
with the pT were observed when comparing tissue from 
patients at different RCC progression stages [10]. A 
significant association between TGFBI tissue expression 
with this progressive neoplasm at different stages and with 
its diameter was very recently reported [16]. Moreover, 
urinary levels of AQP1 and PLIN2 were observed to be 
correlated with the tumour size and stage but not with 
grade [17]. However, despite these promising studies, none 
was successfully able to predict RCC aggressiveness, and, 
up to now, tumour size and growth rate are still the most 
used prognostic factors. In addition, currently there is 
only limited literature addressing urine markers for RCC. 
This is noteworthy especially if we consider the benefits 
related to the possibility of following localized tumours or 
monitoring drug-based therapy results by simply analysing 
tumour-specific markers in an easily accessible biofluid 
such as kidney excretory product [20, 21].
In this study, we systematically investigated the urinary 
peptidome of a large cohort of RCC patients in order to 
highlight possible features varying according to tumor 
characteristics: size, stage and grade. To preserve the 
homogeneity of the samples, we included only clear cell 
RCC. Statistical data elaboration was focused on data 
derived from urine samples pre-fractionated using C8 
magnetic beads followed by MALDI profiling analysis. 
Previously, the application of this high-throughput 
approach allowed us to build clusters of urinary peptides 
with high diagnostic performances [12].
Through this strategy, we have observed that the uri-
nary abundance of fifteen and twenty-six peptides var-
ies depending on size and stage, respectively (Additional 
file 1: Table S1A, Additional file 2: Table S2A), and among 
them eight were shared and showed a consistent correla-
tion trend. On the other hand, only few signals displayed 
a significant alteration according to Fuhrman grading 
system (Additional file  3: Table  S3A). Even if Furhman 
grade is one of the most widely accepted histological 
prognostic factors [22], it has to be considered that some 
controversial aspects related to the low accuracy due to 
the grade heterogeneity within the same tumor, and to 
the interobserver and intraobserver variability in assign-
ing tumor grade are present [23].
Moreover, most of these peptides were higher or lower 
represented (p  <  0.05) in urine of RCC patients com-
pared to control subjects (Additional file  1: Table  S1A, 
Additional file 2: Table S2A, Additional file 3: Table S3A). 
Some of them have shown significantly varied urinary 
concentration according to pT or grade (Additional file 2: 
Table  S2B and Additional file  3: Table  S3B, Figs.  1, 2) 
and also at early stages pT1a and pT1b (Additional file 4: 
Table S4).
One of the major advantages of MALDI profiling 
strategy is that signals do not need any prior 
knowledge about their identity  in order to allow their 
use as biomarkers. Nevertheless, the identification 
of endogenous peptides could increase  the biological 
insight, exploring the function and the regulation 
of bioactive molecules and degradome products. 
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Furthermore, the lack of identity carries drawbacks 
for their possible translation into clinical routine 
laboratories. We could identify fifteen peptides whose 
urinary expression was significantly varied with tumour 
size, stage and grade (Additional file 5: Table S5, Figs. 1, 
2). Two of the signals were recognized as fragments 
belonging to highly abundant proteins in urine, FIBA 
and UMOD. However, the other identified peptides 
might be attributed to proteins playing a possible role in 
tumorigenesis, progression and aggressiveness.
In particular, the A1AGx protein, known as a1-acid 
glycoprotein (AGP), is the major member of the APP 
family, and its serum concentrations increase during 
acute-phase reactions [24]. In addition, an increased 
APP response was observed to be associated with 
reduced survival rate, independently from stage of 
malignant disease, including lung, pancreatic, renal, 
and colorectal cancer and lymphoma [24]. Serum AGP 
levels in the patient group (esophagus, gastric, colorectal, 
lung, hepatic, pancreatic carcinoma) did not show any 
statistical difference according to tumour size, stage, and 
clinical status [25]. However, patients with advanced or 
recurrent disease and/or metastasis had higher serum 
levels of AGP. These findings suggest that its serum levels 
may not be necessarily related to disease progression 
[25]. Likewise, we found an increase of the urinary levels 
of the AGP fragment compared to controls, especially 
in the early stage pT1a, that decline continuously from 
pT1 to pT3. A negative variation with tumour size was 
also observed. Alteration of the A1AG1 non-glycosylated 
forms levels with the pT was also reported in tissue of 
RCC patients [10]. The authors investigated tissue from 9 
patients at pT1, pT2 and pT3 and they observed a down-
expression of this protein in patients at pT1 and pT2 but 
not at pT3.
NOTCH2 belongs to the Notch family, including 
NOTCH1, NOTCH2, NOTCH3, and NOTCH4 
receptors. Their extracellular domain after the binding 
with specific ligands induce an alteration of the gene 
expression. The clear role of the notch family in RCC 
is still unknown. However, a down-regulation of the 
expression of Notch receptors and of Notch signalling 
was reported, thus suggesting a possible role in the 
progression of renal cell carcinoma [26]. Recently, a 
specific role for each of the four Notch receptors in 
RCC  has also been shown [27]. These authors showed 
a reduced expression of Nocth1 correlating with an 
increase of the Fuhrman grade and tumour size while 
Notch3 and 4 receptors were directly correlated with 
tumour size. Therefore, they suggested a possible role of 
NOTCHs in tumorigenesis of RCC. Our data shows that 
Notch2 is also involved in RCC progression. In fact, even 
if the urinary NOTCH2 is reduced in patients compared 
to controls, a positive variation and an increase of its 
urinary fragment levels from pT1 to pT3 were observed.
Disintegrin and metalloproteinase 19 (ADAM19) is a 
cell surface glycoprotein belonging to the ADAM fam-
ily. These proteins are known to be involved in cell 
adhesion, fusion, and migration and they have a role in 
cancer cell proliferation and progression [28]. ADAM19 
was described as up-regulated in human brain tumours 
and correlating with its invasiveness. Moreover, high 
expression of ADAM19 was also associated with lung 
and kidney inflammatory and fibrotic processes [29]. 
An overexpression of ADAM19 in endometrial carci-
noma and its correlation with the progression and prog-
nosis [30] as well as in renal cell carcinomas  has been 
reported [31]. No statistical difference in its abundance 
was observed in ccRCC patients but an increment was 
noticed in urine of ccRCC at Grade 4. However, the func-
tions of ADAM19 in cancers still remain to be elucidated.
Complement C1r subcomponent-like protein (C1RL) 
causes the proteolytic cleavage of HP/haptoglobin. The 
complement system is well known to be involved in many 
immune complex-mediated kidney diseases: an excessive 
activation of the alternative complement pathway is asso-
ciated with autosomal dominant polycystic kidney dis-
ease (ADPKD) progression. In fact, levels of the specific 
complement components such as CFB, SERPING1 and 
C9 were found to be increased while C1RL, CD55 and 
CD59 levels were decreased in urine of ADPKD patients. 
We found higher urinary levels of CRL in RCC patients 
than in control subjects that slowly decreased from G1 
to G4. However, its role in cancer is not known and its 
detection in tissue is still under investigation [32].
We observed a statistically significant increase of uri-
nary levels of a peptide at m/z 1826 in ccRCC patients 
compared to control subjects negatively varying with 
grade. The identity of this signal could have originated 
either from PGBM or from ZAG proteins.
Basement membrane-specific heparan sulfate 
proteoglycan core protein (PGBM), belonging to heparin 
sulfate proteoglycan (HSPG) family, has an important role 
in vascularization. It has been shown that heparanase is 
highly expressed with a positive correlation with tumour 
stage and poor prognosis in RCC [33]. Moreover, HSPGs 
have been reported in many metastatic tumours, and 
their expression was observed in a variety of malignant 
tumours, showing correlations with malignant phenotype 
[34]. Higher expression of heparanase in ccRCCs than 
in non-ccRCCs correlating with stage was shown by 
immunostaining and RT-PCR [35]. Furthermore, specific 
silencing of heparanase mRNA expression (786-O 
and Caki-2 cells) with small interfering RNA (siRNA) 
inhibited the invasiveness capabilities of these cells 
in  vitro [35]. Elevated heparanase expression was also 
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shown to be an independent indicator of disease-specific 
survival [35, 36]. These findings suggest an important role 
of heparanase in invasion and metastasis and silencing of 
the gene could represent a potential therapeutic target in 
ccRCCs.
Zinc-alpha-2-glycoprotein (ZA2G, AZGP1, ZAG) is a 
protein associated with lipid mobilization, a process that 
is also regulated by mTOR signaling. A down expres-
sion of the ZA2G was observed in the tissue of patients 
affected by hepatocellular carcinoma (HCC) [37] and 
it was associated with a poor overall survival, worst 
disease-free survival, relapse-free survival and distant 
metastatic progression-free survival. Moreover, ZA2G 
protein was also found to be lower in 57 patients with a 
rising of prostate specific antigen after surgery and not in 
the other 32 patients [38]. ZAG expression was inversely 
correlated with Gleason pattern and correlated with a 
favourable outcome.
MMP23 is a member of matrix metalloproteinase fam-
ily (MMP23A, MMP21, MMP23B, MMP22) that partici-
pates in many aspects of tumour growth and metastasis. 
Altered MMP23 expression has been observed in pros-
tate adenocarcinoma, multiple myeloma, synovial sar-
coma and in colorectal cancers [39–43]. We observed 
that its urinary levels are lower in RCC patients com-
pared to controls and have a negative alteration depend-
ing on tumour size and pT.
Drebrin (DREB) has been recently reported to be over-
expressed in human metastatic colon adenocarcinoma 
cell line HCT-116 [44]. We also detected an increase of 
its urinary levels in ccRCC, especially at grade 4. A pos-
sible role in tumour cell migration and invasion for this 
protein has been shown in glioma. A constant overex-
pression of drebrin in U87 cells caused an alteration in 
cell morphology with an increased invasiveness while a 
silencing of drebrin gene expression decreases the inva-
sion and the migration [45].
Glyceraldehyde-3-phosphate dehydrogenase (G3P) 
is implicated in nuclear functions such as transcription, 
RNA transport, DNA replication and apoptosis. Down-
regulation of its expression was observed in colorectal 
cancer [46] while it was over-expressed in human cancer 
cell lines [47]. Moreover, increased expression of GAPDH 
enhanced aggressiveness and vascularization of non-
Hodgkin’s lymphoma [48].
SAFB1 (scaffold attachment factor B1) and a second 
family member Scaffold attachment factor B2 (SAFB2) 
are multifunctional proteins implicated in a variety 
of cellular processes including cell growth, apoptosis 
and stress response. A possible role for SAFBx as 
tumour suppressors has  also been suggested [49]. 
There is numerous evidence that SAFB1/SAFB2 have a 
contribution in cancer progression. SAFB1/SAFB2 may 
have more complex implications in cellular functions, 
such as RNA processing and metabolism, that could 
potentially affect various signalling pathways in cancer 
[49]. We observed low urinary levels for SAFB2 in 
RCC, patients especially at grade 4. Low SAFB protein 
levels were also suggested as possible predictors of poor 
prognosis of breast cancer [50].
There is a critical need for trials aimed at better defining 
the progression of renal masses as well as finding robust 
indicators of patient outcomes, such as overall survival 
and disease specific survival. These studies should include 
either hypothesis generating or hypothesis testing of lab-
oratory tools, tissue based or circulating biomarkers [51]. 
Moreover, the American Urological Association guide-
lines state that patients undergoing follow-up for treated 
or observed renal masses should undergo basic labora-
tory testing and, depending on the risk, imaging (US, CT 
or MR) every three months in high risks or yearly in low 
risks. However, potential adverse effects and cost should 
also be take into account. Recent attention has been paid 
to the cumulative radiation exposure of the population 
attributable to the widespread and increasing use of CT 
scanning. For MRI, which does not involve the use of 
ionizing radiation, the prime adverse effect to consider is 
the development of nephrogenic systemic fibrosis (NSF) 
due to IV gadolinium administration. No prospective val-
idation currently exists for the use of common laboratory 
parameters in the early detection of metastases or both 
in the staging and monitoring of patients with renal cell 
carcinoma following treatment for recurrence. Moreover, 
the finding of a biological aggressiveness marker is also 
useful considering its role in the active surveillance of the 
appropriately selected small renal mass, limiting adverse 
health outcomes. In this context, it is desirable to gain 
easily accessible, not invasive molecular indicators, which 
correlate with consolidated progression factors, such as 
tumor size, staging and grade. Moreover, an understand-
ing of the complex molecular alterations involved in the 
development and progression of RCC could enable devel-
opment of immunohistochemical and immunoenzymatic 
diagnostic tools and also open the doors for experimental 
targeted therapies.
Conclusions
In this study, we highlight a number of peptides whose 
urinary expression is altered depending on tumor size, 
pT and grade. Among them, several play a possible 
role in tumorigenesis, progression and aggressiveness, 
enriching the molecular scenario of RCC development. 
These results could be a useful starting point for 
future studies aimed at verifying their urinary levels 
by immunoenzymatic assays (i.e. ELISA test) and the 
resulting possibility for some of them to be implemented 
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in progression algorithms for risk stratification of ccRCC 
patients. Moreover, their urinary changes could also be 
useful to the “watch-and-wait approach” for monitoring 
small renal masses and could find a possible role in 
management follow-up strategies (e.g. residual tumors).
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